Anwita Drugs & Chemicals Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
as on 16-11-2024
- Paid Up Capital ₹ 3.50 Cr
as on 16-11-2024
- Company Age 10 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 9.06 Cr
as on 16-11-2024
- Revenue -47.46%
(FY 2023)
- Profit -68.04%
(FY 2023)
- Ebitda 10.63%
(FY 2023)
- Net Worth 2.74%
(FY 2023)
- Total Assets -5.41%
(FY 2023)
About Anwita Drugs & Chemicals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.50 Cr and a paid-up capital of Rs 3.50 Cr.
The company currently has active open charges totaling ₹9.06 Cr.
Kandhagatla Rajnarayana and Kandhagatla Prasad serve as directors at the Company.
- CIN/LLPIN
U24232TG2014PTC092897
- Company No.
092897
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Feb 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Medak, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Anwita Drugs & Chemicals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kandhagatla Rajnarayana  | Director | 12-Feb-2014 | Current |
| Kandhagatla Prasad | Director | 25-Dec-2017 | Current |
Financial Performance of Anwita Drugs & Chemicals.
Anwita Drugs & Chemicals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 47.46% decrease. The company also saw a substantial fall in profitability, with a 68.04% decrease in profit. The company's net worth moved up by a moderate rise of 2.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anwita Drugs & Chemicals?
In 2023, Anwita Drugs & Chemicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Synerzys Novaceuticals Private LimitedActive 9 years 7 monthsKandhagatla Rajnarayana is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 30 Jun 2020 | ₹1.00 M | Open |
Indian Bank Creation Date: 01 Sep 2015 | ₹8.96 Cr | Open |
How Many Employees Work at Anwita Drugs & Chemicals?
Anwita Drugs & Chemicals has a workforce of 56 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anwita Drugs & Chemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anwita Drugs & Chemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
